- Home
- PHUN vs ICCM Comparison
PHUN vs ICCM Comparison
Compare PHUN & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- ICCM
- Stock Information
- Founded
- PHUN 2009
- ICCM 2006
- Country
- PHUN United States
- ICCM Israel
- Employees
- PHUN N/A
- ICCM N/A
- Industry
- PHUN EDP Services
- ICCM
- Sector
- PHUN Technology
- ICCM
- Exchange
- PHUN Nasdaq
- ICCM Nasdaq
- Market Cap
- PHUN 55.9M
- ICCM 61.1M
- IPO Year
- PHUN N/A
- ICCM N/A
- Fundamental
- Price
- PHUN $2.69
- ICCM $0.82
- Analyst Decision
- PHUN Buy
- ICCM Strong Buy
- Analyst Count
- PHUN 2
- ICCM 1
- Target Price
- PHUN $7.75
- ICCM $2.50
- AVG Volume (30 Days)
- PHUN 250.8K
- ICCM 2.4M
- Earning Date
- PHUN 11-06-2025
- ICCM 11-25-2025
- Dividend Yield
- PHUN N/A
- ICCM N/A
- EPS Growth
- PHUN N/A
- ICCM N/A
- EPS
- PHUN N/A
- ICCM N/A
- Revenue
- PHUN $2,400,000.00
- ICCM $2,787,000.00
- Revenue This Year
- PHUN N/A
- ICCM $3.95
- Revenue Next Year
- PHUN $72.40
- ICCM $266.15
- P/E Ratio
- PHUN N/A
- ICCM N/A
- Revenue Growth
- PHUN N/A
- ICCM N/A
- 52 Week Low
- PHUN $2.22
- ICCM $0.51
- 52 Week High
- PHUN $14.60
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- PHUN 43.25
- ICCM 31.55
- Support Level
- PHUN $2.80
- ICCM $0.79
- Resistance Level
- PHUN $3.13
- ICCM $0.90
- Average True Range (ATR)
- PHUN 0.18
- ICCM 0.09
- MACD
- PHUN -0.02
- ICCM -0.02
- Stochastic Oscillator
- PHUN 8.00
- ICCM 4.77
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.